Jubilant Ingrevia Limited (JUBLINGREA) Fair Value & Analysis
Basic Materials · IN · Market cap ₹106B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated yesterday
Share price +7.6% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹534.80 – ₹818.92 · fair‑value band ₹258.57 – ₹484.57 · the ₹670.80 price screens above the ₹383.89 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Jubilant Ingrevia Limited (JUBLINGREA) currently trades at ₹670.80, while our model-based Fair Value estimate is ₹383.89 — implying the stock looks roughly 42.8% overvalued today. We read business quality at 54/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Jubilant Ingrevia Limited generated revenue of ₹43.9B at a net margin of 6.3%. Revenue grew 12.1% year over year. It earns a return on equity of 9.2%. Net debt stands at ₹6.0B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. The company operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. In addition, it provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. The company serves pharmaceutical, nutrition, agrochemical, consumer, and industrial sectors. The company was formerly known as Jubilant …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Jubilant Ingrevia Limited reported revenue of ₹43.9B in FY2026 versus ₹49.1B in FY2022, a compound −2.8%/yr. Reported net income was ₹2.8B in FY2026, compounding −12.6%/yr from FY2022.
Is JUBLINGREA fairly valued? → Check now
Similar stocks
6 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $507.90 | $142.21 | -72% |
| L'Air Liquide S.A AIQUY | $37.93 | $15.46 | -59% |
| Air Products and Chemicals, Inc A1PD34 | R$360.05 | R$108.63 | -70% |
| Intercontinental Exchange, Inc I1CE34 | R$367.00 | R$311.38 | -15% |
| Wanhua Chemical Group 600309 | ¥74.30 | ¥68.03 | -8% |
| Asian Paints Limited ASIANPAINT | ₹2,715 | ₹655.71 | -76% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Jubilant Ingrevia Limited (JUBLINGREA) undervalued?
What is the fair value of JUBLINGREA?
What is the quality score of JUBLINGREA?
What is the revenue of Jubilant Ingrevia Limited (JUBLINGREA)?
What is the net profit margin of JUBLINGREA?
Does Jubilant Ingrevia Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.